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Smoking imposes a huge economic burden on society—
currently up to 15% of total healthcare costs in developed
countries. Smoking cessation can save years of life, at a very low
cost compared with alternative interventions. This chapter
reviews some of the economic aspects of smoking cessation.
Who benefits from cessation?
The most obvious benefits of smoking cessation are
improvements in life expectancy and prevention of disease.
However, cessation also improves individuals’ quality of life as
smokers tend to have a lower self reported health status than
non-smokers, and this improves after stopping smoking.
There are also wider economic benefits to individuals and
society, arising from reductions in the effects of passive smoking
in non-smokers and savings to the health service and the
employer. These wider benefits are often omitted from
economic evaluations of cessation interventions, which
consequently tend to underestimate the true value for money
afforded by such programmes.
Economic burden of smoking
Many estimates have been made of the economic cost of
smoking in terms of health resources. For the United States
they typically range from about 0.6% to 0.85% of gross
domestic product. In absolute terms, the US public health
service estimates a total cost of $50bn (£29bn; €42bn) a year for
the treatment of smoking related diseases, in addition to an
annual $47bn in lost earnings and productivity. Estimated total
costs in Australia and Canada, as a proportion of their gross
domestic product, are 0.4% and 0.56% respectively. In the
United Kingdom, the treatment of smoking related disease has
been estimated to cost the NHS £1.4bn-£1.5bn a year (about
0.16% of the gross domestic product)—including £127m to treat
lung cancer alone.
When expressed as a percentage of gross domestic product,
the economic burden of smoking seems to be rising. In reality,
however, the burden may not be increasing, but instead, as more
diseases are known to be attributable to smoking, the burden
attributed to smoking increases. Earlier estimates may simply
have underestimated the true cost.
Passive smoking
In the United States, passive smoking has been estimated to
be responsible for 19% of total expenditure on childhood
respiratory conditions, and maternal smoking has been shown
to increase healthcare expenditure by $120 a year for children
under age 5 years and $175 for children under age 2 years.
In the United Kingdom an estimated £410m a year is spent
treating childhood illness related to passive smoking; in adults,
passive smoking accounts for at least 1000 deaths in
non-smokers, at an estimated cost of about £12.8m a year at
2002 prices.
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Benefits of smoking cessation
Smokers and their families
• Improved quality and quantity of life for those stopping smoking
• Improved quality and quantity of life for those living with smokers
through a reduction in the harm from passive smoking
Society
• Lower healthcare expenditure on treatment of smoking induced
disease
• Less workplace absenteeism due to smoking related disease
• Less harm from passive smoking in public places
• Reduction in costs related to cleaning up after smokers (cigarette
ends, ash, etc and damage from these to floors and furnishings)
In Puerto Rico, China (above), and Venezuela, the cost of smoking has been
estimated as 0.3%-0.43% of the gross domestic product
Passive smoking causes illness and premature loss of life,
at all ages from the prenatal period to late adult life
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Cost of absenteeism
Absenteeism arising from smoking related disease is also a major
cause of lost productivity, a cost incurred by employers. An
annual estimated 34 million days are lost in England and Wales
through sickness absence resulting from smoking related illness,
and in Scotland the cost of this productivity loss is about £400m.
Cost effectiveness of cessation
programmes
Clear evidence exists that smoking cessation interventions are
effective. However, to show value for money, the costs as well as
the effectiveness of such programmes have to be examined. The
overwhelming evidence is that face to face cessation
interventions provide excellent value for money compared with
the great majority of other medical interventions.
Several complex factors influence cost effectiveness. For
example, although a cessation programme tends to be more
effective as its intensity increases, increased intensity is
associated with increased costs, therefore increasing both sides
of the cost effectiveness ratio. This was illustrated in a study by
Parrott et al (1998) of the range of intensities of smoking
cessation interventions in the United Kingdom. The researchers
examined these interventions using local cost data and life years
saved as predicted from the PREVENT simulation model. They
looked at four interventions: a basic intervention of three
minutes of opportunistic brief advice; brief advice plus self help
material; brief advice plus self help material and nicotine
replacement products; and brief advice plus self help material,
nicotine replacement products, and a recommendation to
attend a smoking cessation clinic. The most cost effective
intervention was the brief advice alone (cost £159 per life year
saved, £248 when discounted at 6%), although the most
intensive clinical interventions still represent good value for
money at £1002 per life year saved when discounted at 6%.
The cost effectiveness of putting the US Agency for
Healthcare Research and Quality’s clinical guidelines on
smoking cessation into practice has also been estimated, for
combined interventions based on smokers’ preferences for
different types of the five basic recommended interventions.
The cost of implementation was estimated at $6.3bn in the first
year, as a result of which society would gain 1.7 million new
quitters at an average cost of $3779 per quitter, $2587 per life
year saved, and $1915 per quality adjusted life year (QALY). In
this study the most intensive interventions were calculated to be
more cost effective than the briefer therapies.
Care should be taken when extrapolating the results of
these evaluations, as cost effectiveness estimates are likely to be
time and country specific and highly dependent on the
healthcare system in question. In a system of fee for service, as
in the United States, monetary rewards may be necessary to
encourage provision. On the other hand, if patients who stop
smoking place a reduced burden on the primary care budget in
future years, the incentives to provide such services may be
inherent in the system.
Pharmacological interventions
The National Institute for Clinical Excellence (NICE) has
recently estimated the cost effectiveness of using nicotine
replacement therapy (NRT) or bupropion therapy. These
estimates projected life years saved over a shorter period than
the PREVENT model and hence produced generally higher
figures: £1000-£2400 per life year saved for advice and NRT,
Cost effectiveness estimates for healthcare providers
Type of intervention
Costs per life year saved (£)
Undiscounted Discounted
Face to face
Brief advice 159 248
Brief advice plus self help 195 303
Brief advice plus self help plus NRT 524 815
Brief advice plus self help plus NRT
plus specialist cessation service
658 1022
Community
“Quit and win” programme:
Medium intensity 634 986
“No smoking” day 26 40
Broader community health
promotion interventions
(medium intensity)
192 295
NRT= nicotine replacement therapy. Data from Parrott et al, 1998 (see Further
Reading box), revised to reflect 2001-2 prices.
Cost per year of life saved (£000s)
0.1 1 10 100
Aspirin after myocardial infarction
Gaspoz et al (N Engl J Med 2002;346:1800)
Simvastatin after myocardial infarction
Jonsson et al (Eur Heart J 1996;17:1001)
Brief advice + self help + NRT +
specialist support
Brief advice + self help + NRT
Brief advice + self help
Brief advice
Pravastatin primary prevention
Caro et al (BMJ 1997;315:1577)
Cost effectiveness of smoking cessation interventions compared with that of
routine strategies for preventing myocardial infarction
Smoking related fires cause about £151m of damage each
year in England and Wales
The National Institute for Clinical Excellence is part of
the NHS in England and Wales; it issues guidance on
current “best practice”
Discounting is a method of adjusting for the fact that
individuals prefer to incur costs in later periods and
enjoy benefits in the current period. Applying a discount
rate transforms future values into current values, taking
this preference into account
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£645-£1500 for advice plus bupropion, and £890-£1970 for
advice, nicotine replacement, and bupropion. When QALYs are
used, the ranges are £741-£1780, £473-£1100, and £660-£1460
respectively. These costs again compare favourably with a range
of other healthcare interventions. Bupropion does seem more
cost effective than NRT, although the evidence base for the
effectiveness of bupropion is much less extensive than for NRT,
and results should therefore be treated with caution.
The cost effectiveness of bupropion has been investigated in
Spain with a decision model (Musin et al, eighth meeting of the
Society for Research on Nicotine and Tobacco, Savannah,
2002). The model presents results in an incremental analysis
over and above opportunistic advice in primary care. The
findings show that if all motivated smokers in Spain were to use
the therapy, over a 20 year period 44 235 smoking related
deaths would be averted at a saving to the healthcare system of
€1.25bn. In the United States, studies have predicted savings of
between $8.8m and $14m over 20 years when bupropion is
added to an insurance plan. In a UK study, Stapleton et al
(1999) used data from a randomised placebo controlled trial of
nicotine patches and a survey of resource use to show that if
general practitioners were allowed to prescribe transdermal
nicotine patches on the NHS for 12 weeks, the cost per life year
saved would be £398 for people aged under 35, £345 for those
aged 35-44, £432 for those aged 45-54, and £785 for those aged
55-65. Since Stapleton’s study was published, NRT has been
made available in Britain through NHS prescription. However,
studies have tended to exclude potential side effects of
bupropion and are again based on a more limited effectiveness
database then the evidence for the effectiveness of NRT
products.
The means by which the provision is financed is a crucial
determinant of the effectiveness of smoking cessation products.
Evidence shows that smokers are more likely to take up
smoking cessation interventions if they are provided by their
insurance scheme or health service than if they have to pay for
them themselves. In the United Kingdom, NHS provision can
reduce costs through bulk buying and discounts from
pharmaceutical manufacturers. The price for a packet of seven
15 mg Nicorette patches, for example, costs £15.99 through
retail outlets, compared with an NHS purchase price of only
£9.07, a reduction of about 43%. It is also clear that decreases in
the price of NRT products and increases in the price of
cigarettes would lead to substantial increases in per capita sales
of NRT products.
The photograph of the Marlboro advertisement in China is published
with permission from Mark Henley/Panos.
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Key points
• Savings to the healthcare system, a reduction in the harm caused
by passive smoking, and savings to employers are all relevant in
evaluations of cessation interventions
• The economic cost of smoking in the United States may be as high
as 1.15% of gross domestic product in terms of healthcare costs
alone
• The estimated cost to the NHS is £1.4bn-£1.5bn
• Cessation interventions offer excellent value for money when
compared with some other healthcare interventions
• Some studies have quantified outcomes in life years saved, not
allowing for changes in quality of life, thereby underestimating the
cost effectiveness of smoking cessation by almost half
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Comparative costs of other common healthcare treatments
(analysis of guidance of the National Institute for Clinical
Excellence)
Intervention
Incremental cost (£)
Per quality
adjusted
life year
Per life
year gained
Zanamivir in managing influenza 9300-31 500
Taxanes for ovarian cancer 6500-10 000
Taxanes for breast cancer 7000-24 000
Implantable cardioverter
defibrillators for arrhythmias
26 000-31 000
Glycoprotein IIb/IIIa inhibitors for
acute coronary syndromes
7000-12 000
Methylphenidate for
attention-deficit/hyperactivity
disorder in children
10 000-15 000
Tribavirin and interferon alfa for hepatitis C:
First six months’ treatment 3000-7000
Second six months’ treatment 5000-36 000
Laparoscopic surgery for inguinal
hernias
50 000
Riluzole for motor neurone disease 34 000-43 000
Orlistat for obesity in adults 20 000-30 000
Adapted from Raftery (BMJ 2001;323:1300-3).
Clinical review
949BMJ VOLUME 328 17 APRIL 2004 bmj.com
